Clinical trial
Randomised Study to Compare the Efficacy of AZD6244 vs TMZ
NCT00338130 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00338130 |
|---|---|
| Title | Randomised Study to Compare the Efficacy of AZD6244 vs TMZ |
| Official title | A Phase II, Multi-centre, Open-Label, Parallel Group, Randomised Study To Compare the Efficacy of AZD6244 vs Temozolomide in Patients With Unresectable AJCC Stage 3 or 4 Malignant Melanoma |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Drug |
| Interventions | AZD6244, Temozolomide |
| Enrollment | 239 |
| Start date | Jul 1, 2006 |
| Primary completion | Sep 1, 2007 |
| Completion | Jul 1, 2013 |
| First posted | Jun 20, 2006 |
| Last update posted | Aug 13, 2014 |
| Countries | Argentina, Australia, Austria, Brazil, Canada, Denmark, France, Switzerland, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: